BWX Technologies, Inc. - BWXT STOCK NEWS

BWX Technologies reported Q3 2021 earnings with a GAAP EPS of $0.63 and non-GAAP EPS of $0.76, with total revenue of $499 million, down 4% year-over-year. The company returned $166 million to shareholders through stock repurchases, while narrowing non-GAAP EPS guidance to $3.05, the low end of its previous range. Revenue from its Nuclear Operations Group remained stable, but the Nuclear Power Group saw a 23% revenue drop. Cash from operations was $67.3 million, significantly up from the previous year.

BWX Technologies, Inc. (NYSE: BWXT) has secured a significant contract with the U.S. Department of Energy valued at up to $21 billion over a 10-year period for environmental management at the Savannah River Site in South Carolina. This contract is part of a joint venture including BWXT and other partners, focusing on liquid waste management and nuclear materials stabilization. The president of BWXT's Nuclear Services Group emphasized the win's strategic importance in tackling environmental challenges while committing to effective collaboration with regulatory bodies and local communities.

BWX Technologies, Inc. (NYSE: BWXT) will announce its third quarter 2021 results on November 1, 2021, after market close. A conference call is scheduled for 5:00 p.m. EDT the same day. Participants can listen via the Internet and join the call using the provided dial-in numbers. BWXT specializes in nuclear solutions supporting global security, clean energy, and environmental remediation, with approximately 6,700 employees across multiple operating sites in the U.S. and Canada.

BWX Technologies, Inc. (NYSE: BWXT) announced its subsidiary, BWXT Medical Ltd., has entered a partnership with Bayer AG to develop Actinium-225 (Ac-225) supply and explore further commercialization opportunities for targeted radionuclide therapies (TRTs). Ac-225 is a potent radioisotope used in targeted alpha therapies for tumors. BWXT Medical aims to leverage its partnerships for processing and manufacturing at its facilities. This collaboration is expected to advance both companies' growth strategies in the expanding TRT market, which shows significant potential for future development.

NuScale Power is enhancing its manufacturing process at BWXT Canada Ltd.'s facility in Cambridge, Ontario, focusing on the fabrication of its NuScale Power Module™. This step is significant for the development of small modular reactor (SMR) technology and showcases NuScale's effort to establish a robust Canadian supply chain. BWXT Canada was engaged for an 18-month design contract, with further manufacturing agreements expected. The company emphasizes its capacity to source 80% of the plant components locally, aiming for Canadian deployment of the SMR technology by 2028.

BWX Technologies, Inc. (NYSE: BWXT) has secured a contract from Bruce Power worth approximately CA$40 million for the supply of four moderator heat exchangers. The contract will be implemented by BWXT Canada Ltd. at its Cambridge, Ontario facility, covering engineering and fabrication. Deliveries are planned for 2024 and 2025. This contract is expected to support a significant number of skilled jobs at BWXT’s Cambridge operations, contributing to reliable and non-emitting electricity generation in Ontario.

BWX Technologies reported Q2 2021 revenue of $505 million, unchanged from Q2 2020. Net income was $59.3 million or $0.62 per diluted share, down from $64.3 million or $0.67 per diluted share last year. The Nuclear Operations Group saw a 7% revenue decrease to $381 million, while the Nuclear Power Group's revenue surged 50% to $102 million. Despite cash from operations falling to $59.9 million from $162 million in Q2 2020, BWXT declared a quarterly dividend of $0.21 per share, payable on September 8, 2021.

BWX Technologies, Inc. (BWXT) is set to release its second quarter 2021 financial results on August 2, 2021, after the market closes. A conference call will follow at 5:00 p.m. EDT, allowing participants to join and access a supporting presentation online. BWXT, based in Lynchburg, Virginia, specializes in providing nuclear solutions across various sectors, employing approximately 6,700 individuals across 12 major sites in the U.S. and Canada. The company is involved in numerous joint ventures with the U.S. Department of Energy and NASA.

BWXT Medical Ltd. announced a long-term agreement with Boston Scientific to manufacture TheraSphere™ Y-90 Glass Microspheres, aimed at treating hepatocellular carcinoma (HCC). The deal includes substantial investment to automate production at BWXT's Ottawa facility, enhancing capacity to meet growing demand. This follows Boston Scientific's recent FDA PMA approval of TheraSphere, which increases patient access to this treatment. BWXT cautions that various risks may affect production and demand for TheraSphere.